FHTX NASDAQ
Foghorn Therapeutics Inc.
1W: -42.3%
1M: -60.9%
3M: -60.0%
YTD: -61.1%
1Y: -59.0%
3Y: -66.3%
5Y: -85.8%
$2.02
-0.90 (-30.82%)
Weekly Expected Move ±17.6%
$1
$2
$2
$2
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
2 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (43)
Foghorn extends losses as TD Cowen cuts on Lilly exit
Foghorn plunges as Lilly exits collaboration
BlackRock Inc. Takes Position in Foghorn Therapeutics Inc. $FHTX
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates
Acadia Healthcare (ACHC) Surpasses Q2 Earnings and Revenue Estimates
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
12 Health Care Stocks Moving In Friday's After-Market Session
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
Foghorn Therapeutics GAAP EPS of -$0.29, revenue of $3.26M
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 1.9% – Time to Sell?
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
What is HC Wainwright’s Forecast for FHTX FY2026 Earnings?
FY2030 Earnings Estimate for FHTX Issued By HC Wainwright
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates
Foghorn Therapeutics GAAP EPS of -$1.18 misses by $0.08, revenue of $30.91M misses by $0.31M
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
Foghorn Therapeutics appoints Ryan Maynard as CFO
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of “Buy” from Analysts
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?